Sign in
Taking peoplePhase 1

MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia

Key facts

Who runs it
MicrobiotiX Co., Ltd
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
25 Jul 2026
Expected to end
Dec 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MP101
  • Antibiotics
Record updated
28 July 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Subjects aged 19 years or older
  • Clinical diagnosis of acute pneumonia with radiologic evidence of pulmonary infiltrates
  • Confirmed Pseudomonas aeruginosa (PA) infection via valid respiratory specimens
  • PA isolate demonstrates susceptibility to MP101 and non-susceptibility to current antibiotic therapy
  • Adequate organ function as defined by hematological, hepatic, and renal laboratory parameters

Who cannot take part

  • Known hypersensitivity to bacteriophages, study components, or concomitant antibiotics
  • Participation in another clinical trial within 30 days prior to screening
  • Persistent septic shock or hemodynamically unstable condition
  • Active pulmonary tuberculosis or non-bacterial pneumonia
  • Clinically significant cardiovascular, hepatic, or renal impairment
  • Immunocompromised status or hematological malignancies
  • Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study
  • Significant pleural effusion or lung abscess requiring therapeutic drainage

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.

The 3 groups in the trial

  • Low-dose cohort (Cohort A)Treatment being tested

    Participants in the low-dose cohort (Cohort A) will receive a single intravenous infusion of MP101 in addition to standard antibiotic therapy.

    Treatment: MP101 and Antibiotics

  • High-dose cohort (Cohort B)Treatment being tested

    Participants in the high-dose cohort (Cohort B) will receive a single intravenous infusion of MP101 in addition to standard antibiotic therapy.

    Treatment: MP101 and Antibiotics

  • Placebo groupPlacebo, for comparison

    Participants in the placebo group will receive a single intravenous infusion of placebo in addition to standard antibiotic therapy.

    Treatment: Antibiotics

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of MP101 in Adult Patients With Acute Pseudomonas Aeruginosa Pneumonia
Record updated
28 July 2026